HC Wainwright Issues Optimistic Estimate for PepGen Earnings

PepGen, Inc. (NASDAQ:PEPG) – Research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for PepGen in a report released on Thursday, March 5th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.27) per share for the quarter, up from their prior estimate of ($0.52). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.88) EPS, FY2028 earnings at ($1.82) EPS, FY2029 earnings at ($1.43) EPS and FY2030 earnings at ($0.66) EPS.

PEPG has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a research report on Thursday, January 22nd. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Oppenheimer started coverage on PepGen in a research report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Guggenheim upped their price objective on PepGen from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.60.

PepGen Trading Down 1.9%

NASDAQ:PEPG opened at $5.57 on Monday. The company has a market capitalization of $384.94 million, a P/E ratio of -2.31 and a beta of 1.86. The firm has a 50-day moving average price of $5.90 and a two-hundred day moving average price of $4.81. PepGen has a twelve month low of $0.88 and a twelve month high of $7.80.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.13.

Institutional Trading of PepGen

Hedge funds and other institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. lifted its stake in shares of PepGen by 87.7% during the 3rd quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock worth $92,698,000 after purchasing an additional 9,375,000 shares during the period. Commodore Capital LP acquired a new position in PepGen in the third quarter valued at $10,891,000. Vivo Capital LLC acquired a new position in PepGen in the third quarter valued at $10,742,000. Viking Global Investors LP lifted its position in PepGen by 134.9% during the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after buying an additional 2,000,000 shares during the period. Finally, Nantahala Capital Management LLC purchased a new position in PepGen during the fourth quarter worth about $10,072,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).